Mueck A O, Seeger H, Lippert T H
Department of Obstetrics & Gynecology, University of Teubingen, Germany.
Clin Exp Obstet Gynecol. 1998;25(1-2):26-8.
Estrogen replacement therapy in postmenopausal women must be combined with progestin to avoid endometrial cancer. However, progestin addition could antagonize cardioprotective effects of estradiol. Therefore we investigated the effect of the two most commonly used progestins--medroxyprogesterone acetate (progesterone-derivative) and norethisterone acetate (nortestosterone-derivate)--alone and in combination with 17 beta-estradiol on copper-mediated oxidation of low density lipoprotein (LDL). Whereas 17 beta-estradiol alone inhibited the onset of LDL oxidation at the concentrations 0.5, 1.0, 5 and 10 microM, the progestins alone did not demonstrate any significant effect. In the estrogen-progestin combinations of 0.5 microM 17 beta-estradiol with 0.5, 1.0, 5 and 10 microM progestin, respectively, the estradiol effect was not changed. These results suggest that medroxyprogesterone acetate as well as norethisterone acetate do not counteract the beneficial effect of 17 beta-estradiol on LDL oxidation when used in hormone replacement therapy.
绝经后女性的雌激素替代疗法必须与孕激素联合使用以避免子宫内膜癌。然而，添加孕激素可能会拮抗雌二醇的心脏保护作用。因此，我们研究了两种最常用的孕激素——醋酸甲羟孕酮（孕酮衍生物）和醋酸炔诺酮（诺睾酮衍生物）——单独使用以及与17β-雌二醇联合使用对铜介导的低密度脂蛋白（LDL）氧化的影响。单独使用17β-雌二醇时，在浓度为0.5、1.0、5和10微摩尔时可抑制LDL氧化的起始，而单独使用孕激素则未显示出任何显著影响。在分别含有0.5微摩尔17β-雌二醇与0.5、1.0、5和10微摩尔孕激素的雌激素-孕激素组合中，雌二醇的作用未改变。这些结果表明，在激素替代疗法中使用时，醋酸甲羟孕酮以及醋酸炔诺酮不会抵消17β-雌二醇对LDL氧化的有益作用。
